HUAKANG(SH:605077) Shang Hai Zheng Quan Bao·2025-07-01 21:00Core Points - The announcement details the conversion results of the "Huakang Convertible Bonds" issued by Zhejiang Huakang Pharmaceutical Co., Ltd. as of June 30, 2025 [1] Summary by Sections Convertible Bond Issuance Overview - The company issued convertible bonds on December 25, 2023, with a total scale of RMB 1,303.023 million, with a face value of RMB 100 per bond [4] - The bonds have a maturity period of up to 6 years, from December 25, 2023, to December 24, 2029, with a tiered interest rate structure [4] Conversion Status - As of June 30, 2025, a total of RMB 778,000 of the "Huakang Convertible Bonds" has been converted into company shares, representing 0.0597% of the total bond issuance [2][7] - The number of shares converted is 46,054, which is 0.0151% of the total shares outstanding before conversion [2][7] - No conversions occurred during the quarter from April 1, 2025, to June 30, 2025 [3][6] Unconverted Bonds - As of June 30, 2025, the amount of unconverted "Huakang Convertible Bonds" stands at RMB 1,302.245 million, accounting for 99.9403% of the total issuance [3][7] Share Price Adjustments - The initial conversion price was set at RMB 22.66 per share, which was adjusted to RMB 16.89 on May 28, 2024, and further adjusted to RMB 16.39 on April 24, 2025, and to RMB 16.46 on May 14, 2025, due to various corporate actions [4][5]